In advanced breast cancer, the incidence of bone metastases is 65-75%, and the first symptom is bone metastasis in 27-50% of cases. Bone pain, bone injury, bone-related events and reduced quality of life are common complications of bone metastases from breast cancer. Bone related events include: increased bone pain or new bone pain, pathological fracture, vertebral compression or deformation, spinal cord compression, bone radiotherapy (for bone pain or to prevent pathological fracture or spinal cord compression), progression of bone metastases (new, multiple bone metastases, expansion of existing bone metastases) and hypercalcemia. Bone radionuclide scan (ECT) can be used as the initial screening diagnosis of bone metastases, and X-ray, CT scan or magnetic resonance imaging (MRI) is required to confirm the diagnosis. Of course, positron emission computed tomography (PET-CT) can also be used as a diagnosis. However, it is relatively more expensive. The clinical manifestation of bone metastasis is mainly multiple osteolytic lesions. Characteristically, bone metastases with pain seriously affect the patient’s quality of life, but bone metastases themselves generally do not pose a direct threat to life. There are more effective treatments and patients without combined visceral metastases have a relatively long survival. The goals of treatment for bone metastases are: 1. to relieve pain, restore function and improve quality of life 2.Prevent and treat bone-related events. 3. Control tumor progression and prolong survival. Breast cancer bone metastasis, as recurrent metastatic breast cancer should be viewed as a systemic disease and the treatment includes: 1. chemotherapy, endocrine therapy and molecular targeted therapy, etc. 2.Diphosphonate therapy. 3.Surgical treatment. 4.Radiotherapy. 5.Analgesia and other supportive treatments. Treatment should be individualized. The principle of treatment should be systemic treatment, of which chemotherapy, endocrine therapy, and molecular targeted therapy are used as basic drug therapy, while bisphosphonate therapy can be administered to prevent and treat bone-related events. Appropriate local treatment can better control the symptoms of bone metastases, of which surgery is an active treatment for single bone metastases and radiation therapy is an effective local control treatment. Treatment should also take into account the patient’s hormone receptor status (ER/PR) within the tumor tissue, Her-2 status, age, menstrual status, and whether the disease is progressing slowly. In principle, endocrine therapy is preferred for hormone-responsive patients with slow disease progression, chemotherapy is preferred for those with rapid disease progression, and Her-2 overexpression can be considered either alone or in combination with the targeted therapy Herceptin. Bisphosphonates are stable analogs of pyrophosphate molecules. Osteoclasts accumulate in the mineralized bone matrix and lead to bone resorption through enzymatic hydrolysis, and bisphosphonates inhibit osteoclast-mediated bone resorption. Bisphosphonates inhibit osteoclast maturation, inhibit the function of mature osteoclasts, inhibit osteoclast aggregation at the site of bone resorption, and inhibit tumor cell spreading, infiltration, and adhesion to the bone matrix. The main purpose of using bisphosphonates in breast cancer bone metastases is to reduce the incidence of bone-related events, while treating bone pain and hypercalcemia. The main drugs currently available are the second-generation pamiphosphoric acid dinas and alanophosphoric acid dinas. as well as the third-generation zolay phosphate and iban phosphate. Pamidophosphoric acid dinar is administered intravenously at 60-90 mg per dose over an infusion period of not less than 3 hours, every 3-4 weeks. Zolay Phosphate IV, 4 mg per dose, infusion time greater than 15 minutes, every 3-4 weeks. Iban Phosphate intravenous drip, 6 mg per drip, infusion time greater than 15 minutes, every 3-4 weeks. Duration of dosing should be at least 6 months. Indications for discontinuation include: 1. Adverse reactions monitored during use and clearly associated with bisphosphonates; 2. Progressive tumor worsening and life-threatening metastases to other organs during treatment; 3. Clinicians believe that it can be discontinued. 4.But the relief of bone pain after other treatments is not an indication for discontinuation.